Mantle cell lymphoma

Cortelazzo, Sergio; Ponzoni, Maurilio; Ferreri, Andrés J.M.; Dreyling, Martin

doi:10.1016/j.critrevonc.2011.05.001

Cited by 77 publications

(71 citation statements)

References 225 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1 Mantle-cell lymphoma most often aff ects men older than 60 years, generally presents as late-stage disease, and has a median overall survival of 4-5 years. 2 Patients with relapsed disease respond poorly to chemotherapy and progress rapidly, resulting in a median overall survival of 1-2 years.…”

Section: Introductionmentioning

confidence: 99%

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…1 In previous population-based series, the median age at diagnosis was 70 years, with a male/female ratio of 2.3-2.5:1. [2][3][4] The majority of patients are diagnosed with stage IV disease, and the clinical presentation frequently includes lymphadenopathy and extra-nodal involvement, especially of the bone marrow and gastrointestinal tract.…”

Section: Introductionmentioning

confidence: 99%

“…1 For the small portion of patients with limited stage disease, optimal treatment is still not defined.…”

Section: Introductionmentioning

confidence: 99%

Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study

Abrahamsson

Albertsson-Lindblad

Brown

et al. 2014

Blood

118

126

View full text Add to dashboard Cite

• Rituximab and autologous stem cell transplantation are both independently associated with improved overall survival in mantle cell lymphoma.• Male gender is an independent negative prognostic factor in mantle cell lymphoma.There is consensus that young patients with mantle cell lymphoma (MCL) should receive intensive immunochemotherapy regimens, but optimal treatment of elderly patients as well for as patients with limited or indolent disease is not defined. Our aim was to evaluate and compare outcome in relation to prognostic factors and first-line treatment in patients with MCL in a population-based data set. Data were collected from the Swedish and Danish Lymphoma Registries from the period of 2000 to 2011. A total of 1389 patients were diagnosed with MCL. During this period, age-standardized incidence MCL increased, most prominently among males. Furthermore, male gender was associated with inferior overall survival (OS) in multivariate analysis (hazard ratio [HR] 5 1.36; P 5 .002). Forty-three (3.6%) patients with stage I-II disease received radiotherapy with curative intent, showing a 3-year OS of 93%. Twenty-nine (2.4%) patients followed a watch-and-wait approach and showed a 3-year OS of 79.8%. Among patients receiving systemic treatment, rituximab (n 5 766; HR 5 0.66; P 5 .001) and autologous stem cell transplant (n 5 273; HR 5 0.55; P 5 .004) were independently associated with improved OS in multivariate analysis. Hence, by a population-based approach, we were able to provide novel data on prognostic factors and primary treatment of MCL, applicable to routine clinical practice. (Blood. 2014;124(8):1288-1295

show abstract

“…Although a comprehensive discussion of these topics is beyond the scope of this review, several excellent reviews have been published recently. [1][2][3][4] Biological and clinical spectrum of MCL MCL comprises 5% to 6% of new non-Hodgkin lymphoma diagnoses in the United States, ϳ 5000 new cases annually. Patients are typically Ͼ 60 years of age, with a male predominance and advanced-stage disease at diagnosis.…”

Section: Introductionmentioning

confidence: 99%

Transplantation for mantle cell lymphoma: is it the right thing to do?

Williams

2013

Hematology

View full text Add to dashboard Cite

Mantle cell lymphoma (MCL) is a unique subtype of non-Hodgkin lymphoma that is both biologically and clinically heterogeneous. A variety of biomarkers, the achievement of minimal residual disease negativity after initial therapy, and the MCL International Prognostic Index (MIPI) are associated with patient outcome, although none has as yet been used for routine treatment stratification. Given the lack of widely accepted and standardized treatment approaches, clinical trial enrollment should always be considered for the initial therapy of MCL. Outside of the trial setting, younger and transplantation-eligible patients with newly diagnosed MCL who require treatment should first be considered for a rituximab ϩ a high-dose cytarabine-containing regimen, followed by autologous stem cell transplantation consolidation in first remission. Symptomatic elderly and nontransplantation-eligible individuals typically receive rituximab ϩ bendamustine, or R-CHOP (rituximab ϩ cyclophosphamide, hydroxydaunorubicin, vincristine, prednisone/ prednisolone) followed by maintenance rituximab, the latter a treatment plan that has demonstrated extended response duration and survival. Promising early results for consolidation approaches with proteasome inhibitors and immunomodulatory drugs are now being tested in randomized clinical trials. The availability of highly active BCR signaling pathway inhibitors and cell death pathway modulation via BH3 mimetics, among other novel agents, promise to rapidly expand treatment options, change existing treatment paradigms, and further improve outcomes for MCL patients.

show abstract

Mantle cell lymphoma

Cited by 77 publications

References 225 publications

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study

Transplantation for mantle cell lymphoma: is it the right thing to do?

Contact Info

Product

Resources

About